DiaMedica-Logo.png
DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
December 07, 2018 07:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...
DiaMedica-Logo.png
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
November 12, 2018 16:45 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
November 06, 2018 17:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual...
DiaMedica-Logo.png
DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
September 27, 2018 08:52 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS and SHANGHAI, China, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Ahon Pharmaceutical Co Ltd.(Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma, HKG: 02196...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
September 05, 2018 08:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as...
DiaMedica-Logo.png
DiaMedica Issues Stock Option Grant
August 23, 2018 19:30 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and...
DiaMedica-Logo.png
DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
May 03, 2018 08:30 ET | DiaMedica Therapeutics Inc.
DiaMedica has received final minutes from Type B meeting with the US FDADiaMedica preparing to submit an IND to initiate DM199 clinical study in patients with chronic kidney disease in the US ...
DiaMedica-Logo.png
DiaMedica Issues Stock Option Grants
April 17, 2018 21:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX-V:DMA) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
April 05, 2018 07:15 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Final Closing of Private Placement
March 29, 2018 18:08 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...